LinkedIn Profile

Access Patrys historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:patrys 2261413 May 31st, 2019 12:00AM Patrys Limited 415 8.00 Open Biotechnology May 30th, 2019 08:53PM May 30th, 2019 08:53PM Based in Melbourne, Australia, Patrys is a publically-listed company on the Australian Securities Exchange (ASX: PAB) drug development company focused on commercialising antibody therapies for oncology. Listed since 2007, Patrys has two technology platforms: IgM monoclonal antibodies and suite of nuclear penetrating antibodies for cancer therapy. Patrys has successfully out-licensed a clinical candidate for the Chinese market and conducted two clinical trials with another lead candidate from its IgM platform. More recently, Patrys in-licensed from Yale University a suite of novel nucleus-penetrating antibodies (Deoxymab and 5C6) which it will progress through development. Patrys will continue to advance lead candidates from both its technology platforms towards the market, either self-funded or co-developed, and welcomes discussions with interested parties on development. Open Cancer Antibodies, Cancer Therapeutics Open Level 4, 100 Albert Road, South Melbourne Melbourne VIC AU 3205 Patrys Health Care Equipment & Services
private:patrys 2261413 Feb 17th, 2018 12:00AM Patrys Limited 374 8.00 Open Biotechnology Feb 17th, 2018 02:25PM Feb 17th, 2018 02:25PM Based in Melbourne, Australia, Patrys is a publically-listed company on the Australian Securities Exchange (ASX: PAB) drug development company focused on commercialising antibody therapies for oncology. Listed since 2007, Patrys has two technology platforms: IgM monoclonal antibodies and suite of nuclear penetrating antibodies for cancer therapy. Patrys has successfully out-licensed a clinical candidate for the Chinese market and conducted two clinical trials with another lead candidate from its IgM platform. More recently, Patrys in-licensed from Yale University a suite of novel nucleus-penetrating antibodies (Deoxymab and 5C6) which it will progress through development. Patrys will continue to advance lead candidates from both its technology platforms towards the market, either self-funded or co-developed, and welcomes discussions with interested parties on development. Patrys Health Care Equipment & Services
private:patrys 2261413 Feb 16th, 2018 12:00AM Patrys Limited 374 8.00 Open Biotechnology Feb 16th, 2017 08:15AM Feb 16th, 2017 08:15AM Based in Melbourne, Australia, Patrys is a publically-listed company on the Australian Securities Exchange (ASX: PAB) drug development company focused on commercialising antibody therapies for oncology. Listed since 2007, Patrys has two technology platforms: IgM monoclonal antibodies and suite of nuclear penetrating antibodies for cancer therapy. Patrys has successfully out-licensed a clinical candidate for the Chinese market and conducted two clinical trials with another lead candidate from its IgM platform. More recently, Patrys in-licensed from Yale University a suite of novel nucleus-penetrating antibodies (Deoxymab and 5C6) which it will progress through development. Patrys will continue to advance lead candidates from both its technology platforms towards the market, either self-funded or co-developed, and welcomes discussions with interested parties on development. Patrys Health Care Equipment & Services
private:patrys 2261413 Feb 15th, 2018 12:00AM Patrys Limited 374 8.00 Open Biotechnology Feb 15th, 2017 10:07AM Feb 15th, 2017 10:07AM Based in Melbourne, Australia, Patrys is a publically-listed company on the Australian Securities Exchange (ASX: PAB) drug development company focused on commercialising antibody therapies for oncology. Listed since 2007, Patrys has two technology platforms: IgM monoclonal antibodies and suite of nuclear penetrating antibodies for cancer therapy. Patrys has successfully out-licensed a clinical candidate for the Chinese market and conducted two clinical trials with another lead candidate from its IgM platform. More recently, Patrys in-licensed from Yale University a suite of novel nucleus-penetrating antibodies (Deoxymab and 5C6) which it will progress through development. Patrys will continue to advance lead candidates from both its technology platforms towards the market, either self-funded or co-developed, and welcomes discussions with interested parties on development. Patrys Health Care Equipment & Services
private:patrys 2261413 Feb 14th, 2018 12:00AM Patrys Limited 374 8.00 Open Biotechnology Feb 14th, 2017 01:50PM Feb 14th, 2017 01:50PM Based in Melbourne, Australia, Patrys is a publically-listed company on the Australian Securities Exchange (ASX: PAB) drug development company focused on commercialising antibody therapies for oncology. Listed since 2007, Patrys has two technology platforms: IgM monoclonal antibodies and suite of nuclear penetrating antibodies for cancer therapy. Patrys has successfully out-licensed a clinical candidate for the Chinese market and conducted two clinical trials with another lead candidate from its IgM platform. More recently, Patrys in-licensed from Yale University a suite of novel nucleus-penetrating antibodies (Deoxymab and 5C6) which it will progress through development. Patrys will continue to advance lead candidates from both its technology platforms towards the market, either self-funded or co-developed, and welcomes discussions with interested parties on development. Patrys Health Care Equipment & Services
private:patrys 2261413 Feb 13th, 2018 12:00AM Patrys Limited 374 8.00 Open Biotechnology Feb 13th, 2017 04:11PM Feb 13th, 2017 04:11PM Based in Melbourne, Australia, Patrys is a publically-listed company on the Australian Securities Exchange (ASX: PAB) drug development company focused on commercialising antibody therapies for oncology. Listed since 2007, Patrys has two technology platforms: IgM monoclonal antibodies and suite of nuclear penetrating antibodies for cancer therapy. Patrys has successfully out-licensed a clinical candidate for the Chinese market and conducted two clinical trials with another lead candidate from its IgM platform. More recently, Patrys in-licensed from Yale University a suite of novel nucleus-penetrating antibodies (Deoxymab and 5C6) which it will progress through development. Patrys will continue to advance lead candidates from both its technology platforms towards the market, either self-funded or co-developed, and welcomes discussions with interested parties on development. Patrys Health Care Equipment & Services
private:patrys 2261413 Feb 12th, 2018 12:00AM Patrys Limited 374 8.00 Open Biotechnology Feb 12th, 2017 04:15AM Feb 12th, 2017 04:15AM Based in Melbourne, Australia, Patrys is a publically-listed company on the Australian Securities Exchange (ASX: PAB) drug development company focused on commercialising antibody therapies for oncology. Listed since 2007, Patrys has two technology platforms: IgM monoclonal antibodies and suite of nuclear penetrating antibodies for cancer therapy. Patrys has successfully out-licensed a clinical candidate for the Chinese market and conducted two clinical trials with another lead candidate from its IgM platform. More recently, Patrys in-licensed from Yale University a suite of novel nucleus-penetrating antibodies (Deoxymab and 5C6) which it will progress through development. Patrys will continue to advance lead candidates from both its technology platforms towards the market, either self-funded or co-developed, and welcomes discussions with interested parties on development. Patrys Health Care Equipment & Services
private:patrys 2261413 Feb 11th, 2018 12:00AM Patrys Limited 374 8.00 Open Biotechnology Feb 11th, 2017 05:35AM Feb 11th, 2017 05:35AM Based in Melbourne, Australia, Patrys is a publically-listed company on the Australian Securities Exchange (ASX: PAB) drug development company focused on commercialising antibody therapies for oncology. Listed since 2007, Patrys has two technology platforms: IgM monoclonal antibodies and suite of nuclear penetrating antibodies for cancer therapy. Patrys has successfully out-licensed a clinical candidate for the Chinese market and conducted two clinical trials with another lead candidate from its IgM platform. More recently, Patrys in-licensed from Yale University a suite of novel nucleus-penetrating antibodies (Deoxymab and 5C6) which it will progress through development. Patrys will continue to advance lead candidates from both its technology platforms towards the market, either self-funded or co-developed, and welcomes discussions with interested parties on development. Patrys Health Care Equipment & Services
private:patrys 2261413 Feb 10th, 2018 12:00AM Patrys Limited 374 8.00 Open Biotechnology Feb 10th, 2017 06:43AM Feb 10th, 2017 06:43AM Based in Melbourne, Australia, Patrys is a publically-listed company on the Australian Securities Exchange (ASX: PAB) drug development company focused on commercialising antibody therapies for oncology. Listed since 2007, Patrys has two technology platforms: IgM monoclonal antibodies and suite of nuclear penetrating antibodies for cancer therapy. Patrys has successfully out-licensed a clinical candidate for the Chinese market and conducted two clinical trials with another lead candidate from its IgM platform. More recently, Patrys in-licensed from Yale University a suite of novel nucleus-penetrating antibodies (Deoxymab and 5C6) which it will progress through development. Patrys will continue to advance lead candidates from both its technology platforms towards the market, either self-funded or co-developed, and welcomes discussions with interested parties on development. Patrys Health Care Equipment & Services
private:patrys 2261413 Feb 9th, 2018 12:00AM Patrys Limited 374 8.00 Open Biotechnology Feb 9th, 2017 08:57AM Feb 9th, 2017 08:57AM Based in Melbourne, Australia, Patrys is a publically-listed company on the Australian Securities Exchange (ASX: PAB) drug development company focused on commercialising antibody therapies for oncology. Listed since 2007, Patrys has two technology platforms: IgM monoclonal antibodies and suite of nuclear penetrating antibodies for cancer therapy. Patrys has successfully out-licensed a clinical candidate for the Chinese market and conducted two clinical trials with another lead candidate from its IgM platform. More recently, Patrys in-licensed from Yale University a suite of novel nucleus-penetrating antibodies (Deoxymab and 5C6) which it will progress through development. Patrys will continue to advance lead candidates from both its technology platforms towards the market, either self-funded or co-developed, and welcomes discussions with interested parties on development. Patrys Health Care Equipment & Services

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.